Peptides that divert HIV proteins so virus particles stay noninfectious
Inducing Off-pathway Assembly of HIV Gag Polyprotein with Computationally Designed Peptides
This project uses computer-designed peptides to push HIV’s building blocks to assemble incorrectly so the virus can’t make infectious particles, aiming to help people living with HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11136529 on NIH RePORTER |
What this research studies
From my point of view, researchers are designing small protein pieces (peptides) on a computer to stick to HIV’s Gag protein and steer it into wrong shapes. Those peptides can form fibers, sheets, or liquid droplets that trap viral components and prevent normal virus formation. The team will test these peptides in the lab to see whether they reliably force HIV into noninfectious assemblies across many genetic variants. If the lab work is promising, the approach could move toward models or clinical development later on.
Who could benefit from this research
Good fit: People living with HIV, including those with drug-resistant virus, would be the potential beneficiaries or future candidates for therapies developed from this work.
Not a fit: People without HIV and those needing immediate clinical treatments should not expect direct benefit from this early laboratory-focused project.
Why it matters
Potential benefit: If successful, this could become a new antiviral strategy that disables many viral variants and may be harder for HIV to evade with resistance mutations.
How similar studies have performed: Targeting HIV capsid and assembly is an emerging area with some promising small-molecule drugs, but using designed peptides to force misassembly is a newer strategy that is largely untested in patients.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Villegas, Jose Abraham — University of Illinois at Chicago
- Study coordinator: Villegas, Jose Abraham
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.